Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)

  Measured over: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years

• Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)

  Measured over: DLTs are assessed during the first cycle (28 days) in each cohort

• Part 2, Arm 1: Objective Response Rate (ORR)

  Measured over: Up to 1.5 years

• Part 2, Arms 2-4: Number of Participants with DLTs

  Measured over: DLTs are assessed during the first cycle (28 days) in arms 2-4

• Part 2, Arms 2-5: Number of Participants with TEAEs

  Measured over: From first dose until the end of the safety follow-up period (60 days after last dose), up to approximately 5 years

Changes Tremor has spotted